1. Pink Sheet
  2. >>Archive

Discussing CER Communications Asymmetry Is Putting The Cart Before The Horse – UPenn’s Caplan

 
• By Gregory Twachtman

Current comparative research lacks firm quality data standards, including what would be considered accurate CER. Caplan notes that in today’s research environment, standards are determined by the peer review process and have no consistent application and no regulation. Before asymmetry can be addressed, these standards need to be determined.

Any debate on the asymmetry in the ability to discuss comparative effectiveness research findings is premature, considering there are no standards for how the research is conducted, University of Pennsylvania professor of bioethics Arthur Caplan said.

Speaking at the Feb. 9 “Asymmetry in the Ability to Communicate CER Findings: Ethics and Issues for Informed Decision Making”...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.